Pavel Raifeld

Pavel Raifeld

Amministratore Delegato presso INNOVIVA, INC.

Patrimonio netto: 6 M $ in data 31/05/2026

42 anni
Health Technology
Consumer Services
Finance

Profilo

Pavel Raifeld is currently Chief Executive Officer & Director at La Jolla Pharmaceutical Co. since 2023, Chief Executive Officer & Director at Innoviva, Inc. since 2025, Chief Executive Officer at Theravance Respiratory Co. LLC, President & Director at Tetraphase Pharmaceuticals, Inc., President & Director at Entasis Therapeutics Holdings, Inc. since 2022, and President & Director at Entasis Therapeutics, Inc. Formerly, Mr. Raifeld was Senior Member-Healthcare Investment Banking at Credit Suisse Securities (USA) LLC.
Education includes an MBA from The Trustees of Columbia University in The City of New York and undergraduate studies at Harvard University.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
20/05/2026 285.929 ( 0,39% ) 6 M $ 31/05/2026

Posizioni attive di Pavel Raifeld

SocietàPosizioneInizio
INNOVIVA, INC. Amministratore Delegato 20/05/2020
ENTASIS THERAPEUTICS HOLDINGS INC. Presidente 11/07/2022
LA JOLLA PHARMACEUTICAL COMPANY Amministratore Delegato 01/04/2023
TETRAPHASE PHARMACEUTICALS, INC. Presidente -
Amministratore Delegato -
Presidente -

Precedenti posizioni note di Pavel Raifeld

SocietàPosizioneFine
Corporate Officer/Principal -
Vedi nel dettaglio l'esperienza di Pavel Raifeld

Formazione di Pavel Raifeld

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

17

Relazioni di 1° grado

9

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private9

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

  1. Mercati
  2. Insiders
  3. Pavel Raifeld